Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2017 Filed Jun 12, 2017 20:10 UTC |
Pierce David ASVP and President, Endoscopy
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,062 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001225208-17-011120 · doc4.xml · derivative · entry 5 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,934 Underlying: Common Stock · 4,062 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 20:10 UTC |
Pierce David ASVP and President, Endoscopy
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 9,500 | $0.00 Strike: $13.08 | $0.00 |
DisclosureSEC source: 0001225208-17-011120 · doc4.xml · derivative · entry 4 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,929 Underlying: Common Stock · 9,500 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 20:10 UTC |
Pierce David ASVP and President, Endoscopy
|
SaleCommon Stock | 13,562 | $28.00 | $379,736.00 |
DisclosureSEC source: 0001225208-17-011120 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 20:10 UTC |
Pierce David ASVP and President, Endoscopy
|
Exercise / conversionCommon Stock | 4,062 | $7.39 | $30,018.18 |
DisclosureSEC source: 0001225208-17-011120 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 20:10 UTC |
Pierce David ASVP and President, Endoscopy
|
Exercise / conversionCommon Stock | 9,500 | $13.08 | $124,260.00 |
DisclosureSEC source: 0001225208-17-011120 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 20:17 UTC |
Pierce David ASVP and President, Endoscopy
|
SaleCommon Stock | 2,972 | $27.70 | $82,313.40 |
DisclosureSEC source: 0001225208-17-010882 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F2 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| June 01, 2017 Filed Jun 1, 2017 20:08 UTC |
Pratt Timothy A.EVP, GC & Chief Admin Officer
|
SaleCommon Stock | 10,000 | $27.13 | $271,261.00 |
DisclosureSEC source: 0001225208-17-010717 · doc4.xml · nonDerivative · entry 1 Pratt Timothy A. · CIK 0001432178 · EVP, GC & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,846 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at $27.10 and $27.1521. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:17 UTC |
Pierce David ASVP and President, Endoscopy
|
Exercise / conversionDeferred Stock Units · Derivative | 2,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-010882 · doc4.xml · derivative · entry 4 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,889 Underlying: Common Stock · 2,972 shares Expires 2021-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:17 UTC |
Pierce David ASVP and President, Endoscopy
|
Tax withholdingCommon Stock | 1,399 | $27.61 | $38,626.39 |
DisclosureSEC source: 0001225208-17-010882 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,173 Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:17 UTC |
Pierce David ASVP and President, Endoscopy
|
Exercise / conversionCommon Stock | 2,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-010882 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:17 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Exercise / conversionDeferred Stock Units · Derivative | 1,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-010881 · doc4.xml · derivative · entry 4 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,045 Underlying: Common Stock · 1,761 shares Expires 2021-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:17 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Tax withholdingCommon Stock | 829 | $27.61 | $22,888.69 |
DisclosureSEC source: 0001225208-17-010881 · doc4.xml · nonDerivative · entry 2 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,541 Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:17 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Exercise / conversionCommon Stock | 1,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-010881 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| May 30, 2017 Filed May 30, 2017 20:15 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,500 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-17-010514 · doc4.xml · derivative · entry 4 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,835 Underlying: Common Stock · 15,500 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the grant. Read SEC document |
| May 30, 2017 Filed May 30, 2017 20:15 UTC |
Phalen Michael P.EVP & President, MedSurg
|
SaleCommon Stock | 15,500 | $27.25 | $422,368.80 |
DisclosureSEC source: 0001225208-17-010514 · doc4.xml · nonDerivative · entry 2 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,919 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $27.23 to $27.2717, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| May 30, 2017 Filed May 30, 2017 20:15 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionCommon Stock | 15,500 | $7.16 | $110,980.00 |
DisclosureSEC source: 0001225208-17-010514 · doc4.xml · nonDerivative · entry 1 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| May 17, 2017 Filed May 18, 2017 20:25 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
SaleCommon Stock | 16,088 | $26.18 | $421,116.27 |
DisclosureSEC source: 0001225208-17-010054 · doc4.xml · nonDerivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,366 F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $26.17 to $26.181, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| May 17, 2017 Filed May 18, 2017 20:25 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
SaleCommon Stock | 12,776 | $26.09 | $333,337.34 |
DisclosureSEC source: 0001225208-17-010054 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,454 F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at $26.09 and $26.10. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| May 09, 2017 Filed May 11, 2017 20:31 UTC |
Zane Ellen MDirector
|
GrantCommon Stock | 7,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009509 · doc4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,944 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 09, 2017 Filed May 11, 2017 20:31 UTC |
Sununu John EDirector
|
GrantCommon Stock | 7,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009508 · doc4.xml · nonDerivative · entry 1 Sununu John E · CIK 0001458974 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,156 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 09, 2017 Filed May 11, 2017 20:31 UTC |
ROUX DAVID JDirector
|
GrantCommon Stock | 7,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009507 · doc4.xml · nonDerivative · entry 1 ROUX DAVID J · CIK 0001234273 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,906 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 09, 2017 Filed May 11, 2017 20:31 UTC |
MACMILLAN STEPHEN PDirector
|
GrantDeferred Stock Units · Derivative | 3,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009506 · doc4.xml · derivative · entry 2 MACMILLAN STEPHEN P · CIK 0001239351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,696 Underlying: Common Stock · 3,790 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · shares: Reflects a value of $100,000 divided by the closing price of common stock on the date of grant. F5 · derivative.exercise_date: Deferred stock units were granted in lieu of 100% of the cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F5 · derivative.expiration_date: Deferred stock units were granted in lieu of 100% of the cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| May 09, 2017 Filed May 11, 2017 20:31 UTC |
MACMILLAN STEPHEN PDirector
|
GrantDeferred Stock Units · Derivative | 7,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009506 · doc4.xml · derivative · entry 1 MACMILLAN STEPHEN P · CIK 0001239351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,906 Underlying: Common Stock · 7,012 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| May 09, 2017 Filed May 11, 2017 20:31 UTC |
LUDWIG EDWARD JDirector
|
GrantCommon Stock | 7,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009505 · doc4.xml · nonDerivative · entry 1 LUDWIG EDWARD J · CIK 0001221783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,829 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 09, 2017 Filed May 11, 2017 20:31 UTC |
FUJIMORI YOSHIAKIDirector
|
GrantDeferred Stock Units · Derivative | 7,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009504 · doc4.xml · derivative · entry 1 FUJIMORI YOSHIAKI · CIK 0001233160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,012 Underlying: Common Stock · 7,012 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| May 09, 2017 Filed May 11, 2017 20:30 UTC |
JAMES DONNADirector
|
GrantCommon Stock | 7,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009503 · doc4.xml · nonDerivative · entry 1 JAMES DONNA · CIK 0001197735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,770 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 09, 2017 Filed May 11, 2017 20:30 UTC |
Dockendorff Charles JDirector
|
GrantCommon Stock | 7,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009502 · doc4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,104 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 09, 2017 Filed May 11, 2017 20:29 UTC |
Connors Nelda JDirector
|
GrantCommon Stock | 7,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009501 · doc4.xml · nonDerivative · entry 1 Connors Nelda J · CIK 0001478748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,333 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 03, 2017 Filed May 18, 2017 20:25 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
GiftCommon Stock | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-010054 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,230 F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| May 01, 2017 Filed May 2, 2017 20:11 UTC |
Pratt Timothy A.EVP, GC & Chief Admin Officer
|
SaleCommon Stock | 10,000 | $26.37 | $263,728.00 |
DisclosureSEC source: 0001225208-17-008856 · doc4.xml · nonDerivative · entry 1 Pratt Timothy A. · CIK 0001432178 · EVP, GC & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,846 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| May 01, 2017 Filed May 2, 2017 20:11 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,500 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-17-008857 · doc4.xml · derivative · entry 4 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,335 Underlying: Common Stock · 15,500 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the grant. Read SEC document |
| May 01, 2017 Filed May 2, 2017 20:11 UTC |
Phalen Michael P.EVP & President, MedSurg
|
SaleCommon Stock | 15,500 | $26.37 | $408,778.40 |
DisclosureSEC source: 0001225208-17-008857 · doc4.xml · nonDerivative · entry 2 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,919 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| May 01, 2017 Filed May 2, 2017 20:11 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionCommon Stock | 15,500 | $7.16 | $110,980.00 |
DisclosureSEC source: 0001225208-17-008857 · doc4.xml · nonDerivative · entry 1 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| April 26, 2017 Filed Apr 27, 2017 20:10 UTC |
Pierce David ASVP and President, Endoscopy
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,250 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001225208-17-008531 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,996 Underlying: Common Stock · 10,250 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| April 26, 2017 Filed Apr 27, 2017 20:10 UTC |
Pierce David ASVP and President, Endoscopy
|
SaleCommon Stock | 10,250 | $26.00 | $266,500.00 |
DisclosureSEC source: 0001225208-17-008531 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,600 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| April 26, 2017 Filed Apr 27, 2017 20:10 UTC |
Pierce David ASVP and President, Endoscopy
|
Exercise / conversionCommon Stock | 10,250 | $7.39 | $75,747.50 |
DisclosureSEC source: 0001225208-17-008531 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| April 26, 2017 Filed Apr 27, 2017 20:10 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 34,773 | $0.00 Strike: $12.52 | $0.00 |
DisclosureSEC source: 0001225208-17-008530 · doc4.xml · derivative · entry 4 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,773 shares Expires 2018-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2009. This option is fully vested. Read SEC document |
| April 26, 2017 Filed Apr 27, 2017 20:10 UTC |
Phalen Michael P.EVP & President, MedSurg
|
SaleCommon Stock | 34,773 | $26.00 | $904,098.00 |
DisclosureSEC source: 0001225208-17-008530 · doc4.xml · nonDerivative · entry 2 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,919 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| April 26, 2017 Filed Apr 27, 2017 20:10 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionCommon Stock | 34,773 | $12.52 | $435,357.96 |
DisclosureSEC source: 0001225208-17-008530 · doc4.xml · nonDerivative · entry 1 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| April 24, 2017 Filed Jul 2, 2018 20:28 UTC |
Sununu John EDirector
|
PurchaseCommon Stock | 29 | $25.52 | $740.08 |
DisclosureSEC source: 0001225208-18-011026 · doc4.xml · nonDerivative · entry 1 Sununu John E · CIK 0001458974 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,294 F1 · kind: These shares were acquired by, and held in, a managed account. F2 · balance_after: Reflects transactions that have taken place since the date of this transaction and which have been previously reported on Form 4. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 20:11 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
SaleCommon Stock | 2,950 | $24.66 | $72,747.00 |
DisclosureSEC source: 0001225208-17-007963 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,980 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 20:09 UTC |
Pratt Timothy A.EVP, GC & Chief Admin Officer
|
SaleCommon Stock | 10,000 | $24.87 | $248,725.00 |
DisclosureSEC source: 0001225208-17-007381 · doc4.xml · nonDerivative · entry 1 Pratt Timothy A. · CIK 0001432178 · EVP, GC & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,846 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at $24.85 and $24.895. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 20:08 UTC |
MACMILLAN STEPHEN PDirector
|
GrantStock Option (Right to Buy) · Derivative | 827 | $0.00 Strike: $24.92 | $0.00 |
DisclosureSEC source: 0001225208-17-007643 · doc4.xml · derivative · entry 2 MACMILLAN STEPHEN P · CIK 0001239351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827 Underlying: Common Stock · 827 shares Expires 2027-04-03 F4 · shares: Reporting person received 25% of the cash compensation for the first quarter of 2017 in the form of an option to purchase a specified number of shares of common stock vesting in full upon the 2017 annual meeting of stockholders. F4 · derivative.exercise_date: Reporting person received 25% of the cash compensation for the first quarter of 2017 in the form of an option to purchase a specified number of shares of common stock vesting in full upon the 2017 annual meeting of stockholders. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 20:08 UTC |
MACMILLAN STEPHEN PDirector
|
GrantDeferred Stock Units · Derivative | 677 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-007643 · doc4.xml · derivative · entry 1 MACMILLAN STEPHEN P · CIK 0001239351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,894 Underlying: Common Stock · 677 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: Reflects a value of $16,875 divided by the closing price of common stock on the date of grant. F3 · derivative.exercise_date: Deferred stock units were granted in lieu of 75% of the quarterly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F3 · derivative.expiration_date: Deferred stock units were granted in lieu of 75% of the quarterly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| March 29, 2017 Filed Mar 30, 2017 20:37 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 46,500 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-17-007048 · doc4.xml · derivative · entry 4 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,835 Underlying: Common Stock · 46,500 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the grant. Read SEC document |
| March 29, 2017 Filed Mar 30, 2017 20:37 UTC |
Phalen Michael P.EVP & President, MedSurg
|
SaleCommon Stock | 79,045 | $24.55 | $1,940,341.33 |
DisclosureSEC source: 0001225208-17-007048 · doc4.xml · nonDerivative · entry 2 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,919 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 29, 2017 Filed Mar 30, 2017 20:37 UTC |
Phalen Michael P.EVP & President, MedSurg
|
Exercise / conversionCommon Stock | 46,500 | $7.16 | $332,940.00 |
DisclosureSEC source: 0001225208-17-007048 · doc4.xml · nonDerivative · entry 1 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 03, 2017 Filed Mar 3, 2017 22:50 UTC |
Pierce David ASVP and President, Endoscopy
|
SaleCommon Stock | 25,012 | $25.01 | $625,667.68 |
DisclosureSEC source: 0001225208-17-005553 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · SVP and President, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,600 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 03, 2017 Filed Mar 3, 2017 22:50 UTC |
Pratt Timothy A.EVP, GC & Chief Admin Officer
|
SaleCommon Stock | 23,540 | $25.01 | $588,846.04 |
DisclosureSEC source: 0001225208-17-005552 · doc4.xml · nonDerivative · entry 1 Pratt Timothy A. · CIK 0001432178 · EVP, GC & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,846 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 23:07 UTC Amendment |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
GrantStock Option (Right to Buy) · Derivative | 52,816 | $0.00 Strike: $24.98 | $0.00 |
DisclosureSEC source: 0001225208-17-005662 · doc4a.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,816 Underlying: Common Stock · 52,816 shares Expires 2027-03-03 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.